Advertisement

Behçet Disease

  • Ahmet Gül
Chapter

Abstract

Behçet disease (BD) is a multifactorial inflammatory disorder characterized by recurrent attacks affecting mucocutaneous and ocular tissues as well as joints, blood vessels, and central nervous and gastrointestinal systems. Although this distinct set of manifestations was first thought to be associated with a generalized viral infection, no specific causative agent could be isolated. But several microorganisms, including uncommon serotypes of streptococcal strains and herpes simplex virus, have been implicated as triggers of disease manifestations in genetically susceptible individuals, and a hypersensitivity to streptococcal antigens and a possible cross-reactivity with self-proteins have been suggested in the pathogenesis of BD. Genetic factors may play a role in susceptibility to certain microbial agents as well as in the hyper-reactive immune response to these pathogens and other dangerous insults. Identification of the genetic and immunologic basis of the disordered host—microbial interactions is expected to provide insights to reduce the impact of BD in the patients as well as in the high-risk populations.

Keywords

Behçet disease Streptococcus sanguinis Herpes simplex virus Heat shock proteins Microbiota Hypersensitivity 

Abbreviations

BD

Behçet disease

HLA

Human leukocyte antigen

HSP60

Heat shock protein 60-kDa

HSP65

Heat shock protein 65-kDa

ICR

Institute of Cancer Research

References

  1. 1.
    Gul A. Pathogenesis of Behcet’s disease: autoinflammatory features and beyond. Semin Immunopathol. 2015;37(4):413–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Behcet H. Über rezidivierende, apthöse durch ein Virus verursachte Geschwüre am Mund, am Auge und an der Genitalen. Dermatol Wochenschr. 1937;105:1152–7.Google Scholar
  3. 3.
    Behcet H, Matteson EL. On relapsing, aphthous ulcers of the mouth, eye and genitalia caused by a virus. 1937. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S2–5.PubMedGoogle Scholar
  4. 4.
    Sezer FN. The isolation of a virus as the cause of Behcet’s diseases. Am J Ophthalmol. 1953;36(3):301–15.CrossRefPubMedGoogle Scholar
  5. 5.
    Sezer N. Further investigations on the virus of Behcet’s disease. Am J Ophthalmol. 1956;41(1):41–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Eglin RP, Lehner T, Subak-Sharpe JH. Detection of RNA complementary to herpes-simplex virus in mononuclear cells from patients with Behcet’s syndrome and recurrent oral ulcers. Lancet. 1982;2(8312):1356–61.CrossRefPubMedGoogle Scholar
  7. 7.
    Young C, Lehner T, Barnes CG. CD4 and CD8 cell responses to herpes simplex virus in Behcet’s disease. Clin Exp Immunol. 1988;73(1):6–10.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Davies UM, Palmer RG, Denman AM. Treatment with acyclovir does not affect orogenital ulcers in Behcet’s syndrome: a randomized double-blind trial. Br J Rheumatol. 1988;27(4):300–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Sohn S. Etiopathology of Behcet’s disease: herpes simplex virus infection and animal model. Yonsei Med J. 1997;38(6):359–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Sohn S, Lee ES, Bang D, Lee S. Behcet’s disease-like symptoms induced by the herpes simplex virus in ICR mice. Eur J Dermatol. 1998;8(1):21–3.PubMedGoogle Scholar
  11. 11.
    Sohn S, Lee ES, Lee S. The correlation of MHC haplotype and development of Behcet’s disease-like symptoms induced by herpes simplex virus in several inbred mouse strains. J Dermatol Sci. 2001;26(3):173–81.CrossRefPubMedGoogle Scholar
  12. 12.
    Buskila D, Gladman DD, Gilmore J, Salit IE. Behcet’s disease in a patient with immunodeficiency virus infection. Ann Rheum Dis. 1991;50(2):115–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Kanazawa H, Ijichi S, Eiraku N, Igakura T, Higuchi I, Nakagawa M, et al. Behcet’s disease and Sjogren syndrome in a patient with HTLV-I-associated myelopathy. J Neurol Sci. 1993;119(1):121–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Park BM, Ahn JS, Lee JB, Won YH, Yun SJ. Chronic active Epstein-Barr virus infection-associated hydroa vacciniforme-like eruption and Behcet’s-like orogenital ulcers. Dermatology. 2013;226(3):212–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Annigeri RA, Rajagopalan M, Mani RM, Kaveripattu SS. Cytomegalovirus infection inducing flare of Behcet’s disease with possible recurrence of glomerulonephritis after renal transplantation. Indian J Nephrol. 2016;26(1):45–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Behcet H. Some observations on the clinical picture of the so-called triple symptom complex. Dermatologica. 1940;81:73–83.CrossRefGoogle Scholar
  17. 17.
    Mumcu G, Ergun T, Inanc N, Fresko I, Atalay T, Hayran O, et al. Oral health is impaired in Behcet’s disease and is associated with disease severity. Rheumatology (Oxford). 2004;43(8):1028–33.CrossRefGoogle Scholar
  18. 18.
    Kaneko F, Oyama N, Yanagihori H, Isogai E, Yokota K, Oguma K. The role of streptococcal hypersensitivity in the pathogenesis of Behcet’s disease. Eur J Dermatol. 2008;18(5):489–98.PubMedGoogle Scholar
  19. 19.
    Kaneko F, Togashi A, Nomura E, Nakamura K. A new diagnostic way for Behcet’s disease: skin prick with self-saliva. Genet Res Int. 2014;2014:1–10.Google Scholar
  20. 20.
    Isogai E, Ohno S, Kotake S, Isogai H, Tsurumizu T, Fujii N, et al. Chemiluminescence of neutrophils from patients with Behcet’s disease and its correlation with an increased proportion of uncommon serotypes of Streptococcus sanguis in the oral flora. Arch Oral Biol. 1990;35(1):43–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Yokota K, Hayashi S, Araki Y, Isogai E, Kotake S, Yoshikawa K, et al. Characterization of Streptococcus sanguis isolated from patients with Behcet’s disease. Microbiol Immunol. 1995;39(9):729–32.CrossRefPubMedGoogle Scholar
  22. 22.
    Narikawa S, Suzuki Y, Takahashi M, Furukawa A, Sakane T, Mizushima Y. Streptococcus oralis previously identified as uncommon ‘Streptococcus sanguis’ in Behcet’s disease. Arch Oral Biol. 1995;40(8):685–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Hirohata S, Oka H, Mizushima Y. Streptococcal-related antigens stimulate production of IL6 and interferon-gamma by T cells from patients with Behcet’s disease. Cell Immunol. 1992;140(2):410–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Yokota K, Hayashi S, Fujii N, Yoshikawa K, Kotake S, Isogai E, et al. Antibody response to oral streptococci in Behcet’s disease. Microbiol Immunol. 1992;36(8):815–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Mizushima Y, Matsuda T, Hoshi K, Ohno S. Induction of Behcet’s disease symptoms after dental treatment and streptococcal antigen skin test. J Rheumatol. 1988;15(6):1029–30.PubMedGoogle Scholar
  26. 26.
    Skin hypersensitivity to streptococcal antigens and the induction of systemic symptoms by the antigens in Behcet’s disease--a multicenter study. The Behcet’s disease research Committee of Japan. J Rheumatol. 1989;16(4):506–11.Google Scholar
  27. 27.
    Hugle T, Bircher A, Walker UA. Streptococcal hypersensitivity reloaded: severe inflammatory syndrome in Behcet’s disease following 23-valent polysaccharide Streptococcus pneumoniae vaccine. Rheumatology (Oxford). 2012;51(4):761–2.CrossRefGoogle Scholar
  28. 28.
    Yoshikawa K, Kotake S, Kubota T, Kimura K, Isogai E, Fujii N. Cloning and sequencing of BeS-1 gene encoding the immunogenic antigen of Streptococcus sanguis KTH-1 isolated from the patients with Behcet’s disease. Zentralbl Bakteriol. 1998;287(4):449–60.CrossRefPubMedGoogle Scholar
  29. 29.
    Lehner T, Lavery E, Smith R, van der Zee R, Mizushima Y, Shinnick T. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behcet’s syndrome. Infect Immun. 1991;59(4):1434–41.PubMedCentralPubMedGoogle Scholar
  30. 30.
    Pervin K, Childerstone A, Shinnick T, Mizushima Y, van der Zee R, Hasan A, et al. T cell epitope expression of mycobacterial and homologous human 65-kilodalton heat shock protein peptides in short term cell lines from patients with Behcet’s disease. J Immunol. 1993;151(4):2273–82.PubMedGoogle Scholar
  31. 31.
    Stanford MR, Kasp E, Whiston R, Hasan A, Todryk S, Shinnick T, et al. Heat shock protein peptides reactive in patients with Behcet’s disease are uveitogenic in Lewis rats. Clin Exp Immunol. 1994;97(2):226–31.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Hu W, Hasan A, Wilson A, Stanford MR, Li-Yang Y, Todryk S, et al. Experimental mucosal induction of uveitis with the 60-kDa heat shock protein-derived peptide 336-351. Eur J Immunol. 1998;28(8):2444–55.CrossRefPubMedGoogle Scholar
  33. 33.
    Stanford M, Whittall T, Bergmeier LA, Lindblad M, Lundin S, Shinnick T, et al. Oral tolerization with peptide 336-351 linked to cholera toxin B subunit in preventing relapses of uveitis in Behcet’s disease. Clin Exp Immunol. 2004;137(1):201–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Calguneri M, Kiraz S, Ertenli I, Benekli M, Karaarslan Y, Celik I. The effect of prophylactic penicillin treatment on the course of arthritis episodes in patients with Behcet’s disease. A randomized clinical trial. Arthritis Rheum. 1996;39(12):2062–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Calguneri M, Ertenli I, Kiraz S, Erman M, Celik I. Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behcet’s disease. Dermatology. 1996;192(2):125–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Mumcu G, Inanc N, Ozdemir FT, Tulunay A, Eksioglu-Demiralp E, Ergun T, et al. Effects of azithromycin on intracellular cytokine responses and mucocutaneous manifestations in Behcet’s disease. Int J Dermatol. 2013;52(12):1561–6.CrossRefPubMedGoogle Scholar
  37. 37.
    Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behcet’s disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J. 1997;38(6):444–54.CrossRefPubMedGoogle Scholar
  38. 38.
    Lule S, Colpak AI, Balci-Peynircioglu B, Gursoy-Ozdemir Y, Peker S, Kalyoncu U, et al. Behcet disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun. 2017;84:87–96.CrossRefPubMedGoogle Scholar
  39. 39.
    Consolandi C, Turroni S, Emmi G, Severgnini M, Fiori J, Peano C, et al. Behcet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269–76.CrossRefPubMedGoogle Scholar
  40. 40.
    Shimizu J, Kubota T, Takada E, Takai K, Fujiwara N, Arimitsu N, et al. Bifidobacteria abundance-featured gut Microbiota compositional change in patients with Behcet’s disease. PLoS One. 2016;11(4):e0153746.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Seoudi N, Bergmeier LA, Drobniewski F, Paster B, Fortune F. The oral mucosal and salivary microbial community of Behcet’s syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015;7:27150.CrossRefPubMedGoogle Scholar
  42. 42.
    Coit P, Mumcu G, Ture-Ozdemir F, Unal AU, Alpar U, Bostanci N, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behcet’s disease. Clin Immunol. 2016;169:28–35.CrossRefPubMedGoogle Scholar
  43. 43.
    Hatemi G, Bahar H, Uysal S, Mat C, Gogus F, Masatlioglu S, et al. The pustular skin lesions in Behcet’s syndrome are not sterile. Ann Rheum Dis. 2004;63(11):1450–2.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Gul A, Inanc M, Ocal L, Aral O, Konice M. Familial aggregation of Behcet’s disease in Turkey. Ann Rheum Dis. 2000;59(8):622–5.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Gul A. Genetics of Behcet’s disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 2014;26(1):56–63.CrossRefPubMedGoogle Scholar
  46. 46.
    Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behcet disease. Proc Natl Acad Sci U S A. 2013;110(20):8134–9.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet’s disease susceptibility. Nat Genet. 2017;49(3):438–43.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Direskeneli H, Mumcu G. A possible decline in the incidence and severity of Behcet’s disease: implications for an infectious etiology and oral health. Clin Exp Rheumatol. 2010;28(4 Suppl 60):S86–90.PubMedGoogle Scholar
  49. 49.
    Kirino Y, Ideguchi H, Takeno M, Suda A, Higashitani K, Kunishita Y, et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet’s disease: a retrospective observational study. Arthritis Res Ther. 2016;18(1):217.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of RheumatologyIstanbulTurkey

Personalised recommendations